Modality Solutions’ New Greenwood Lab Slashes Lead Times and Expands Testing
Modality Solutions is proud to announce the launch of our new Greenwood Lab—a state-of-the-art...
read Details
Modality Solutions new white paper details how simulated transport is a valuable technique for determining the physical stability of drug product protein solutions, including vaccines, monoclonal antibodies, antibody-drug conjugates (ADCs), and gene therapies. Large molecule drug products may be susceptible to degradation when exposed to common transport hazards. Simulation testing exposes the product to the concurrent combination of these hazards at worst-case edges of your operating space in the global supply chain. Unlike ASTM-based testing, the hazards are applied with realistic durations and intensities that reflect the supply chain’s risks.
The white paper explains:
“An understanding of these methodologies is vital to ensure the simulated transport hazards reflect the actual cold chain for each therapy. “If correctly planned and executed to be included in the BLA, analytical results from samples exposed to concurrent transport simulation are considered industry best practice.”
— Modality Solutions President, Gary Hutchinson.
Click here to view the Simulated Transport Methodologies White Paper press release.
Modality Solutions is proud to announce the launch of our new Greenwood Lab—a state-of-the-art...
read DetailsCongratulations to Vertex for their UK approval for CASGEVY™, a CRISPR/Cas9 gene-edited therapy, for...
read DetailsCongratulations to Melinta Therapeutics for their FDA Approval of REZZAYO™ for the Treatment of...
read Details